BS_77317DY4
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 51.05124835742444
- age_years
- 12.956
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.476
- PANCREAS_BETA_CELLS+0.187
- E2F_TARGETS+0.180
- G2M_CHECKPOINT+0.159
- KRAS_SIGNALING_DN+0.119
- SPERMATOGENESIS+0.076
- WNT_BETA_CATENIN_SIGNALING+0.060
- DNA_REPAIR+0.012
- MITOTIC_SPINDLE+0.001
- APICAL_SURFACE-0.061
Top 10 suppressed
- PROTEIN_SECRETION-0.573
- INTERFERON_ALPHA_RESPONSE-0.563
- TNFA_SIGNALING_VIA_NFKB-0.558
- ANDROGEN_RESPONSE-0.519
- OXIDATIVE_PHOSPHORYLATION-0.519
- TGF_BETA_SIGNALING-0.516
- NOTCH_SIGNALING-0.509
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.503
- INTERFERON_GAMMA_RESPONSE-0.497
- INFLAMMATORY_RESPONSE-0.484
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_DBEX7AG2 | Embryonal tumors | — | 0.956 |
| 2 | BS_4W68NV3M | medulloblastoma | — | 0.947 |
| 3 | BS_VPBMDMQX | medulloblastoma | — | 0.941 |
| 4 | MNG459 | — | — | 0.934 |
| 5 | SRR650166 | — | — | 0.933 |
| 6 | BS_1TWCV047 | Embryonal tumors | — | 0.927 |
| 7 | SRR650150 | — | — | 0.926 |
| 8 | SJEPD001543_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.925 |
| 9 | BS_D0RDN4K5 | Embryonal tumors | — | 0.922 |
| 10 | BS_VAAHBH60 | EPN | Supratentorial EPN | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.476 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.187 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.180 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.159 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.119 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.076 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.060 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.012 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.001 | Inavolisib | — uncovered |